[
    [
        {
            "time": "",
            "orginal_text": "医药生物行业2019H1业绩总结：行业增速放缓，龙头引领增长，聚焦创新药产业链、创新生物制品、医疗服务等景气细分赛道",
            "features": {
                "keywords": [
                    "医药生物",
                    "行业增速",
                    "龙头",
                    "创新药",
                    "生物制品",
                    "医疗服务"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "医药生物行业2019H1业绩总结：行业增速放缓，龙头引领增长，聚焦创新药产业链、创新生物制品、医疗服务等景气细分赛道",
            "scores": {
                "News_content": "医药生物行业2019H1业绩总结：行业增速放缓，龙头引领增长，聚焦创新药产业链、创新生物制品、医疗服务等景气细分赛道",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "orginal_text": "郭广昌失策二十年，复星医药市值落后50倍，医药龙头孙飘扬笑了",
            "features": {
                "keywords": [
                    "郭广昌",
                    "复星医药",
                    "市值",
                    "孙飘扬"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "郭广昌失策二十年，复星医药市值落后50倍，医药龙头孙飘扬笑了",
            "scores": {
                "News_content": "郭广昌失策二十年，复星医药市值落后50倍，医药龙头孙飘扬笑了",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "orginal_text": "复星医药:19H1收入增长稳健,费用增加拖累利润 盈利能力下降",
            "features": {
                "keywords": [
                    "复星医药",
                    "收入增长",
                    "费用增加",
                    "盈利能力"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "复星医药:19H1收入增长稳健,费用增加拖累利润 盈利能力下降",
            "scores": {
                "News_content": "复星医药:19H1收入增长稳健,费用增加拖累利润 盈利能力下降",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]